Gemcitabine Plus Nab-Paclitaxel With Hydroxychloroquine in Pancreatic Cancer
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Clinical Trial Design and Patient Characteristics
- June 17, 2019
- Reading time: 2 minutes
On May 23, 2019, JAMA Oncology published Phase II clinical trial results evaluating the efficacy and safety of gemcitabine plus nab-paclitaxel with and without hydroxychloroquine in treatment-naive advanced pancreatic cancer patients. The trial enrolled 112 patients with treatment-naive advanced pancreatic cancer: 55 patients received gemcitabine plus nab-paclitaxel with hydroxychloroquine, and 57 patients received gemcitabine plus nab-paclitaxel without hydroxychloroquine. The primary endpoint was one-year overall survival (OS), with secondary endpoints including progression-free survival (PFS), overall survival duration, and objective response rate (ORR).
Trial Background and Patient Demographics
Mean Age: Hydroxychloroquine group: 64 years; Control group: 65 years
Gender Distribution: Hydroxychloroquine group: 38% female, 62% male; Control group: 40% female, 60% male
Baseline CA19-9 Levels: Hydroxychloroquine group: 2,046 U/mL; Control group: 1,375 U/mL
Tumor Location Distribution:
- Hydroxychloroquine group: pancreatic head 40%, body 36%, tail 24%
- Control group: pancreatic head 51%, body 26%, tail 23%
Clinical Trial Results
Primary Endpoint - One-Year Overall Survival:
- Hydroxychloroquine group: 41%
- Control group: 49%
Secondary Endpoints:
Progression-Free Survival:
- Hydroxychloroquine group: 5.7 months
- Control group: 6.4 months
Overall Survival Duration:
- Hydroxychloroquine group: 11.1 months
- Control group: 12.1 months
Objective Response Rate:
- Hydroxychloroquine group: 38.2%
- Control group: 21.1%
Adverse Events
Both treatment groups experienced similar toxicity profiles, including neutropenia, anemia, fatigue, and peripheral neuropathy. Notable finding: the hydroxychloroquine combination group demonstrated significantly improved objective response rates (38.2% vs. 21.1%), despite comparable one-year overall survival outcomes between groups. The improved tumor response rates with hydroxychloroquine addition warrant further clinical investigation for their potential impact on disease control and subsequent therapeutic interventions.
Data Source
Effect of Gemcitabine and Nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 May 23. doi: 10.1001/jamaoncol.2019.0684.
Related Cancer Treatment
- Clinical Trial Therapeutics
- (Lung Cancer) Topotecan and Topotecan Plus Berzosertib Phase II Clinical Trial Results
- (Lung Cancer) HER2-Mutant Non-Small Cell Lung Cancer Treatment with Enhertu
- (Lung Cancer) Anti-B7-H3 Antibody DS-7300 Clinical Efficacy
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4